Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.

about

Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.

Item

http://www.wikidata.org/entity/Q55493644

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Practice guidelines for manage ...... Oncology Consensus Statement.

@en

Practice guidelines for manage ...... Oncology Consensus Statement.

@nl

type

Item

label

Practice guidelines for manage ...... Oncology Consensus Statement.

@en

Practice guidelines for manage ...... Oncology Consensus Statement.

@nl

prefLabel

Practice guidelines for manage ...... Oncology Consensus Statement.

@en

Practice guidelines for manage ...... Oncology Consensus Statement.

@nl

P1476

Practice guidelines for manage ...... c Oncology Consensus Statement

@en

P2093

Dae Hoon Jeong

http://www.w3.org/2001/XMLSchema#string

Joo Hee Yoon

http://www.w3.org/2001/XMLSchema#string

Sanghoon Lee

http://www.w3.org/2001/XMLSchema#string

Sun Joo Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer

Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement

Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.

Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.

Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.

P304

e56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3802/JGO.2018.29.E56

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29770626

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5981107

http://www.w3.org/2001/XMLSchema#string